Diese Seite wurde automatisch übersetzt und die Genauigkeit der Übersetzung wird nicht garantiert. Bitte wende dich an die englische Version für einen Quelltext.

Verkürztes Behandlungsschema für arzneimittelempfindliche Tuberkulose bei Kindern (SMILE-TB)

6. November 2026 aktualisiert von: Johns Hopkins University

While drug-susceptible tuberculosis (TB) disease in children currently requires four to six months of treatment, most children may be able to be cured with a shorter treatment of more powerful drugs. Shorter treatment may be easier for children to tolerate and finish as well as ease caregiver strain from managing treatment side effects and supporting children over many months. The primary objective of this study is to evaluate if a 2-month regimen (including isoniazid (H), rifapentine (P), pyrazinamide (Z) and moxifloxacin (M)) is as safe and effective as a 4- to 6-month regimen (isoniazid, rifampicin (R), pyrazinamide, ethambutol (E)) in curing drug-susceptible TB disease in children under 10 years old. The study is also evaluating the safety of the HPZM in children with and without HIV.

Studienübersicht

Status

Rekrutierung

Bedingungen

Intervention / Behandlung

Detaillierte Beschreibung

In previously untreated individuals with presumed drug-susceptible pulmonary and or peripheral lymph node TB treated with eight weeks of rifapentine, isoniazid, pyrazinamide and moxifloxacin (2HPZM), all given daily throughout, the proportion of participants who experience absence of cure (unsuccessful outcome) will not be inferior to that observed in participants who are treated with the standard regimen (eight weeks of rifampin, isoniazid, pyrazinamide, with or without ethambutol followed by 8 to 16 weeks of rifampin plus isoniazid depending on disease severity) all given daily throughout.

Studientyp

Interventionell

Einschreibung (Geschätzt)

860

Phase

  • Phase 3

Kontakte und Standorte

Dieser Abschnitt enthält die Kontaktdaten derjenigen, die die Studie durchführen, und Informationen darüber, wo diese Studie durchgeführt wird.

Studienkontakt

  • Name: Kisten Nolan, MPH, BSN
  • Telefonnummer: +14435403993
  • E-Mail: knolan2@jh.edu

Studienorte

      • Chennai, Indien
        • Rekrutierung
        • Indian Council of Medical Research - National Institute for Research in Tuberculosis
        • Kontakt:
        • Hauptermittler:
          • Aishwarya Venkataraman, MBBS, DCH, PgDip PID, MRCPCH
      • Pune, Indien
        • Rekrutierung
        • Dr. D.Y. Patil Medical College, Hospital and Research Center
        • Kontakt:
        • Hauptermittler:
          • Shailaja Mane, MBBS, MD, PGDAP, FRIPH
      • Bandung, Indonesien
        • Rekrutierung
        • Faculty of Medicine, Universitas Padjadjaran
        • Kontakt:
        • Hauptermittler:
          • Rovina Ruslami, MD, PhD
      • Maputo, Mosambik
        • Rekrutierung
        • Instituto Nacional de Saúde (INS)
        • Kontakt:
        • Hauptermittler:
          • Celso Khosa, MD, PhD
      • Lusaka, Sambia
        • Rekrutierung
        • University of Zambia, School of Medicine
        • Kontakt:
          • Chishala Chabala, MBChB MMed MSc
          • Telefonnummer: +260977849537
          • E-Mail: cchabala@gmail.com
        • Hauptermittler:
          • Chishala Chabala, MBChB MMed MSc
      • Ndola, Sambia
        • Rekrutierung
        • Arthur Davison Children's Hospital
        • Kontakt:
      • Durban, Südafrika
        • Rekrutierung
        • Africa Health Research Institute (AHRI)
        • Hauptermittler:
          • Moherndran Archary, MBChB, PhD
        • Kontakt:
      • Kampala, Uganda
        • Rekrutierung
        • MU-JHU Care Ltd
        • Kontakt:
        • Hauptermittler:
          • Eric Wobudeya, MBChB MMed MSc
      • Harare, Zimbabwe
        • Rekrutierung
        • Harare Health and Research Consortium (HHRC)
        • Kontakt:
        • Hauptermittler:
          • Mutsa Bwakura-Dangarembizi, MBChB, MMed (Paeds)

Teilnahmekriterien

Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.

Zulassungskriterien

Studienberechtigtes Alter

1 Sekunde bis 9 Jahre (Kind)

Akzeptiert gesunde Freiwillige

Nein

Studienberechtigte Geschlechter

Alle

Beschreibung

Inclusion Criteria:

  • Parent or guardian is willing and able to provide written informed consent for potential participant's study participation; in addition, when applicable per Ethics Committee/Institutional Review Board (EC/IRB) policies and procedures, potential participant is willing and able to provide assent for study participation.

  • At Entry, age of less than 10 years.

  • At Entry, weight 3 kilograms (kg) or greater.

  • At Entry, diagnosed with TB disease, defined as:

    • Pulmonary (including pleural effusion) and/or lymph node (extra-thoracic and/or intra-thoracic) TB with or without bacteriologic confirmation;
    • Clinician has decided to treat with standard first-line drug-susceptible TB regimen.
  • Known HIV status or HIV testing in progress based on meeting testing requirements.

  • Has normal, Grade 1 or 2 test results for all of the following done at or within 14 days of Entry (including the most recent):

    • Alanine aminotransferase (ALT) less than or equal to 5 times the upper limit of normal;
    • Total bilirubin less than or equal to 2.5 times the upper limit of normal;
    • Potassium level of 3.0 milliequivalent/L or greater;
    • Hemoglobin level of 7.0 g/dL or greater;
    • Platelet count of 100,000/mm3 or greater;
    • Estimated glomerular filtration rate (eGFR; bedside Schwartz formula) 60 mL/min/1.73m2 or higher.
  • For children living with HIV:

    • On antiretroviral therapy (ART) at Entry: Must be on, or able to be switched to a dolutegravir-based regimen at or prior to Entry;
    • Not on ART at Entry: Planned initiation of dolutegravir before or at study Week 4.
  • For participants who have reached menarche or who are engaging in sexual activity (self-reported): negative serum or urine pregnancy test within 7 days of Entry.

  • For participants who are engaging in sexual activity that could lead to pregnancy (self-reported): agrees to practice at least one non-hormonal method of contraception or abstain from heterosexual intercourse during study drug treatment and for 30 days after stopping study medications. Non-hormonal methods include:

    • Male or female condoms
    • Diaphragm or cervical cap (with spermicide, if available)
    • Non-hormonal intrauterine device (IUD) or intrauterine system (IUS)
  • At Entry, intends to remain in the catchment area of the study site for the duration of study follow-up or willingness to be followed up beyond the catchment area if/when applicable, as determined by the site investigator based on participant/parent/guardian report.

Exclusion Criteria:

  • Presumed or documented extra-pulmonary TB involving the central nervous system and/or bones and/or joints, and/or miliary TB, and/or pericardial TB and/or TB of the gastrointestinal (GI) tract and/or renal TB.

  • Premature infant (born less than 37-weeks gestation) who is less than 3 months of age at Entry.

  • Any known contraindication to taking any study drug:

    • Known allergy or intolerance to any of the study drugs or drugs in the same class as the study drugs;
    • Any prohibited medications within three days prior to Entry or planned use within the following 6 months;
    • Unable to take oral medications;
    • Known history of prolonged QT syndrome not caused by electrolyte derangements.
  • Received more than 10 days of treatment directed against TB disease within 6 months preceding initiation of study drugs.

  • M. tuberculosis isolate known or suspected to be resistant to isoniazid, rifampin, pyrazinamide, ethambutol, and/or fluoroquinolones.

  • Known exposure to an infectious adult with drug-resistant TB, including resistance to isoniazid, rifampin, pyrazinamide, ethambutol, and/or fluoroquinolones.

  • Has any other documented or suspected clinically significant medical condition or any other condition that, in the opinion of the site investigator, would make participation in the study unsafe, complicate interpretation of study outcome data, or otherwise interfere with achieving the study objectives.

  • Previously enrolled in this study.

Late Exclusions:

  • M. tuberculosis cultured or detected through World Health Organization (WHO) approved molecular assays (e.g., Cepheid Xpert MTB/RIF, Xpert XDR, sequencing or Hain MTB-DR plus assays) from sputum, swallowed sputum, nasopharyngeal aspirates, stool, or lymph node aspirate obtained around the time of study entry is determined to be resistant to isoniazid and/or rifampin and/or pyrazinamide and/or ethambutol and/or fluoroquinolones.
  • Any child with a clinical TB diagnosis who is found to have a definitive alternative diagnosis for their presenting signs and symptoms whose TB treatment is discontinued prior to completion.

Studienplan

Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.

Wie ist die Studie aufgebaut?

Designdetails

  • Hauptzweck: Behandlung
  • Zuteilung: Zufällig
  • Interventionsmodell: Parallele Zuordnung
  • Maskierung: Keine (Offenes Etikett)

Waffen und Interventionen

Teilnehmergruppe / Arm
Intervention / Behandlung
Aktiver Komparator: Regimen 1: Isoniazid (H), Rifampin (R), Pyrazinamide (Z), Ethambutol (E)

8 weeks of daily HRZ(E) followed by either 16 or 24 weeks of daily HR, per local standard of care

Once daily weight-based dose

Andere Namen:
  • H

Once daily weight-based dose

Andere Namen:
  • R

Once daily weight-based dose

Andere Namen:
  • Z

Once daily weight-based dose

Andere Namen:
  • E
Experimental: Regimen 2: Isoniazid (H), Rifapentine (P), Pyrazinamide (Z), Moxifloxacin (M)

8 weeks of daily HPZM

Once daily weight-based dose

Andere Namen:
  • H

Once daily weight-based dose

Andere Namen:
  • Z

Once daily weight-based dose

Andere Namen:
  • Priftin
  • P

Once daily weight-based dose

Andere Namen:
  • Avelox
  • M

Was misst die Studie?

Primäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
TB disease-free survival at 48-weeks
Zeitfenster: Measured from study entry through week 48

Non-inferiority will be assessed by comparing the upper bound of a 95%, 2-sided confidence interval for the difference between the proportion of participants who are classified as having an unsuccessful outcome on the control regimen (HRZ(E)) and the intervention regimen (HPZM) to the predefined non-inferiority margin of 6% at 48 weeks.

Measured from study entry through week 48
Proportion of participants with grade 3 or higher adverse events over 28 weeks
Zeitfenster: Measured from study entry through Week 28

The proportion of participants with a Grade 3 or higher adverse event and the corresponding 95% confidence intervals will be generated. An exact test for equality of proportions will be used to compare safety outcomes between the arms.

Measured from study entry through Week 28

Sekundäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
TB disease-free survival at 48-weeks
Zeitfenster: Measured from study entry through Week 48

Non-inferiority will be assessed by comparing the upper bound of a 95%, 2-sided confidence interval for the difference between the proportion of participants who are classified as having an unsuccessful outcome on the control regimen (HRZ(E)) and the intervention regimen (HPZM) to the predefined non-inferiority margin of 6% at 48 weeks.

Measured from study entry through Week 48
TB disease-free survival at 72-weeks
Zeitfenster: Measured from study entry through Week 72

Non-inferiority will be assessed by comparing the upper bound of a 95%, 2-sided confidence interval for the difference between the proportion of participants who are classified as having an unsuccessful outcome on the control regimen (HRZ(E)) and the intervention regimen (HPZM) to the predefined non-inferiority margin of 6% at 72 weeks.

Measured from study entry through Week 72
Adherence to treatment regimens
Zeitfenster: Measured from study entry through Week 48

The per-protocol analysis will account for variations in adherence to the treatment regimens. Inverse probability of treatment weighting (IPTW) using propensity scores will be applied and the net difference in treatment failure rates between the two treatment regimens and the 95% confidence interval around this will be calculated to determine non-inferiority.

Measured from study entry through Week 48
Tolerability as assessed by proportion of participants who discontinue treatment
Zeitfenster: Week 8 (intervention/HPZM) or Week 16 or Week 24 (control/HRZ(E))

Tolerability will be assessed as discontinuation of the assigned treatment for a reason other than microbiological ineligibility (AEs assessed as related to the study regimen that led to permanent discontinuation of the regimen, participant refusal, parent/guardian prematurely discontinues, etc.) among the modified intention-to-treat population. Proportion of participants who discontinue the assigned study regimen and the corresponding 95% confidence intervals will be generated. The control regimen (HRZ(E)) will be compared against the intervention regimen (HPZM) using an exact test for equality of proportions.

Week 8 (intervention/HPZM) or Week 16 or Week 24 (control/HRZ(E))
Rifapentine Area under the curve (AUC0-24)
Zeitfenster: Measured from study entry through Week 8

Area under the curve from start of dose to 24 hours post-dose. Measured at Week 4 or Week 8. Blood samples drawn at 0, 1 minute, 2 minutes, 4 hours and 6 hours post dose.

Measured from study entry through Week 8
Rifapentine minimal concentration (Cmin)
Zeitfenster: Measured from study entry through Week 8

Minimal concentration from start of dose to 24 hours post-dose. Measured at Week 4 or Week 8. Blood samples drawn at 0, 1 minute, 2 minutes, 4 hours and 6 hours post dose.

Measured from study entry through Week 8
Rifapentine peak concentration (Cmax)
Zeitfenster: Measured from study entry through Week 8

Peak concentration from start of dose to 24 hours post-dose. Measured at Week 4 or Week 8. Blood samples drawn at 0, 1 minute, 2 minutes, 4 hours and 6 hours post dose.

Measured from study entry through Week 8
Moxifloxacin AUC0-24
Zeitfenster: Measured from study entry through Week 8

Area under the curve from start of dose to 24 hours post-dose. Measured at Week 4 or Week 8. Blood samples drawn at 0, 1 minute, 2 minutes, 4 hours and 6 hours post dose.

Measured from study entry through Week 8
Moxifloxacin Cmin
Zeitfenster: Measured from study entry through Week 8

Minimal concentration from start of dose to 24 hours post-dose. Measured at Week 4 or Week 8. Blood samples drawn at 0, 1 minute, 2 minutes, 4 hours and 6 hours post dose.

Measured from study entry through Week 8
Moxifloxacin Cmax
Zeitfenster: Measured from study entry through Week 8

Peak concentration from start of dose to 24 hours post-dose. Measured at Week 4 or Week 8. Blood samples drawn at 0, 1 minute, 2 minutes, 4 hours and 6 hours post dose.

Measured from study entry through Week 8
Parent/guardian and/or participant reported palatability and acceptability of study regimen
Zeitfenster: Baseline, Week 4, Week 8 (Regimens 1 and 2) and at Weeks 16 and 24 (Regimen 1 only)

Based on questionnaire developed by study team, data will be aggregated to measure acceptability at Entry, Week 4, and Week 8 (all participants), and Weeks 16 and 24 (for those who continue on HRZ(E) only). Scoring based on a likert or likert-like scale for each question. Each question is scored 1 to 5 with higher scores reflecting increased acceptability.

Baseline, Week 4, Week 8 (Regimens 1 and 2) and at Weeks 16 and 24 (Regimen 1 only)
Adherence as assessed by proportion of participants who have taken at least 90% of their doses
Zeitfenster: Baseline through Week 8 for HPZM, Week 16 for HRZ(E) with non-severe disease, or Week 24 for HRZ(E) with severe disease

Adherence measures will be documented by a treatment supporter on a TB treatment card (as per local practice), by pill count and by an adherence questionnaire and descriptively summarized for all participants. Participants are considered adherent who have taken at least 90% of their doses within the 8 week, 16 week or 24-week time frame of their regimen.

Baseline through Week 8 for HPZM, Week 16 for HRZ(E) with non-severe disease, or Week 24 for HRZ(E) with severe disease
Risk Stratification Algorithm
Zeitfenster: Measured from study entry through Week 48

If the study outcome is not non-inferior, pragmatic, programmatically available data will be considered for inclusion in a risk stratification algorithm that would aim to identify children at high risk of unsuccessful TB treatment outcome who may benefit from a longer duration of therapy. The efficacy endpoint will be analyzed using mixed-effects logistic regression models to identify predictors. The models will be adjusted for World Bank country income categories and by site using random intercepts. Univariable and multivariable analysis will be performed. The association between baseline clinical predictors and unsuccessful treatment outcomes will be analyzed, Treatment characteristics will then be added to the models to determine if treatment helped in the description of the primary efficacy endpoint.

Measured from study entry through Week 48
Cost effectiveness as assessed by the incremental cost-effective ratio (ICER)
Zeitfenster: Measured from study entry through Week 24

ICER: Total costs of HPZM minus the total costs 16 or 24 week HRZE, divided by the total number of disability-adjusted life-year (DALY) averted for HPZM minus the total DALYs averted for 16- or 24-week HRZE.

Measured from study entry through Week 24

Andere Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Dolutegravir AUC0-24
Zeitfenster: Measured from study entry through Week 28

Area under the curve from start of dose to 24 hours post-dose. Measured at Week 4 or 8 and at between Weeks 12-28. Blood samples drawn at 0, 1 hour, 4 hours and 6 hours post dose.

Measured from study entry through Week 28
Dolutegravir Cmin
Zeitfenster: Measured from study entry through Week 28

Minimal concentration from start of dose to 24 hours post-dose. Measured at Week 4 or 8 and at between Weeks 12-28. Blood samples drawn at 0, 1 hour, 4 hours and 6 hours post dose.

Measured from study entry through Week 28
Dolutegravir Cmax
Zeitfenster: Measured from study entry through Week 28

Peak concentration from start of dose to 24 hours post-dose. Measured at Week 4 or 8 and at between Weeks 12-28. Blood samples drawn at 0, 1 hour, 4 hours and 6 hours post dose.

Measured from study entry through Week 28
Proportion of children living with HIV
Zeitfenster: Week 24 and Week 48

Among participants living with HIV, the proportions of participants in each study arm who achieve or maintain virologic control (< 200 copies/mL) at Weeks 24 and 48 will be presented in aggregate, as well as broken down by weight bands (if the sample sizes are sufficient) bounded by 95% confidence intervals.

Week 24 and Week 48

Mitarbeiter und Ermittler

Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.

Sponsor

Mitarbeiter

Ermittler

  • Hauptermittler: Nicole Salazar-Austin, MD, ScM, Johns Hopkins University

Publikationen und hilfreiche Links

Die Bereitstellung dieser Publikationen erfolgt freiwillig durch die für die Eingabe von Informationen über die Studie verantwortliche Person. Diese können sich auf alles beziehen, was mit dem Studium zu tun hat.

Allgemeine Veröffentlichungen

Studienaufzeichnungsdaten

Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.

Haupttermine studieren

Studienbeginn (Tatsächlich)

15. Januar 2025

Primärer Abschluss (Geschätzt)

30. September 2027

Studienabschluss (Geschätzt)

30. September 2027

Studienanmeldedaten

Zuerst eingereicht

26. Januar 2024

Zuerst eingereicht, das die QC-Kriterien erfüllt hat

2. Februar 2024

Zuerst gepostet (Tatsächlich)

12. Februar 2024

Studienaufzeichnungsaktualisierungen

Letztes Update gepostet (Tatsächlich)

12. November 2026

Letztes eingereichtes Update, das die QC-Kriterien erfüllt

6. November 2026

Zuletzt verifiziert

1. November 2026

Mehr Informationen

Begriffe im Zusammenhang mit dieser Studie

Andere Studien-ID-Nummern

  • IRB00388853

Plan für individuelle Teilnehmerdaten (IPD)

Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?

JA

Beschreibung des IPD-Plans

Make individual participant data, after de-identification, publicly available in accordance with USAID's policy on data sharing.

IPD-Sharing-Zeitrahmen

After study completion, de-identified data that can be legally released to the public may be released.

IPD-Sharing-Zugriffskriterien

With whom: Researchers who provide a methodologically sound proposal for the use of the data per USAID's policy on data sharing and in accordance with in-country data sharing agreements.

For what types of analysis: To achieve aims specified in the researcher's approved proposal.

By what mechanisms will data be available: To be determined.

Arzneimittel- und Geräteinformationen, Studienunterlagen

Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt

Nein

Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt

Nein

Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .